The FDA issued two draft guidances Friday designed to provide clarity on the agency's recommendations for researching and developing targeted therapies. The first, titled "Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease," proposes an approach for drug developers to enroll patients based on the identification of rare mutations into clinical trials for targeted therapies when reasonable scientific evidence suggests the drug could be effective in patients with those genomic findings.